. Author manuscript; available in PMC: 2011 Jul 13.

Published in final edited form as: N Engl J Med. 2011 Jan 13;364(2):127–135. doi: 10.1056/NEJMoa1001689

Table 4.

Effect of Pharmacologic Interventions on Cholesterol Efflux Capacity.^*

Pharmacologic Intervention	No. of Patients	Percent Change in Cholesterol Efflux Capacity (95% CI)	P Value
Pharmacologic Intervention	No. of Patients	Percent Change in Cholesterol Efflux Capacity (95% CI)	vs. Baseline	vs. Placebo
Thiazolidinedione

Pioglitazone	16	11.3 (1.8 to 20.8)	0.02	0.04

Placebo	23	0.0 (−6.2 to 6.1)	0.99

Statin

Pravastatin, 40 mg	23	−0.4 (−6.5 to 5.6)	0.88	0.71

Atorvastatin, 10 mg	26	2.7 (−4.8 to 10.2)	0.47	0.81

Atorvastatin, 80 mg	25	−2.5 (−9.1 to 4.1)	0.45	0.38

Placebo	25	−1.1 (−6.5 to 4.2)	0.66

Patients treated with pioglitazone received 30 mg per day for 6 weeks, followed by 45 mg per day for an additional 6 weeks. Patients treated with statins received continuous therapy at a fixed dose for 16 weeks.